You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / AUROBINDO PHARMA

AUROBINDO PHARMA
Intrinsic Value | Fundamental Analysis

Returns | 1W : 4.6% , 1M : 13.5%,1Y : 52.4%
BOM : 524804     NSE : AUROPHARMA    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Average
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
May 07,2021
Price(EOD): Rs. 1,012.75
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 59,337.02 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
AUROBINDO PHARMA 4.6% 13.5% 52.4%
SUN PHARMACEUTICAL INDUSTRIES 6% 11.9% 38.7%
DR REDDYS LABORATORIES -0.2% 12% 33.9%
DIVIS LABORATORIES -1.1% 9.2% 77.2%
CIPLA -2.9% 5.6% 49.3%
BIOCON 0.7% -8% 7.5%
LUPIN 11.5% 14.7% 44.7%
TORRENT PHARMACEUTICALS 5% 2.9% 5.5%
CADILA HEALTHCARE 3.9% 32% 84.2%


FUNDAMENTAL ANALYSIS OF AUROBINDO PHARMA

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than AUROBINDO PHARMA Premium


VALUATION OF AUROBINDO PHARMA

 
Valuation Score
Ratio Consolidated
P/E
P/B
P/S
20.96
P/E Calculated based on EPS of 48.32
[ Mar2020 - Consolidated Results ]

3.53
P/B Calculated based on Book Value of 286.92
[ Mar2020 - Consolidated Results ]

2.38
P/S Calculated based on Revenues of 24931.6 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than AUROBINDO PHARMA Premium


FAIR VALUE OF AUROBINDO PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
164%
-0%
20%

SHARE PRICE MOMENTUM OF AUROBINDO PHARMA

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0.29
0.4
0.37
0.35
0.33
0.5
0.41
0.41
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
22.81 %
As on : Mar2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-1.83%
-4.48%
231.26%
258.37%
7.97%
13.29%
328.19%
319.4%
QtrlyTrend
4
Latest Qtr: Dec2020

AUROBINDO PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE DIVIDEND STABILITY 3.6% 5.8% 62.7%
S&P BSE QUALITY 1.9% 3.9% 61.1%
S&P BSE MOMENTUM 1.8% 5.8% 41.6%
S&P BSE SENSEX NEXT 50 1.7% 2.1% 62.7%
S&P BSE HEALTHCARE 1.6% 9.7% 58.6%
S&P BSE LARGECAP 1.5% 1.4% 59%
S&P BSE 100 LARGECAP TMC 1.4% 1.3% 59.2%
S&P BSE LARGE MIDCAP 1.4% 1.3% 61.6%
S&P BSE 200 1.4% 1.4% 62.8%
S&P BSE CARBONEX 1.4% 1.2% 61.2%
S&P BSE 250 LARGEMIDCAP 1.4% 1.4% 63.2%
S&P BSE ALLCAP 1.4% 1.9% 66.8%
S&P BSE 500 1.3% 1.7% 65.5%
S&P BSE 100 1.3% 1.1% 59.5%
NSE Indices1W1M1Y
NIFTY NEXT 50 2.2% 3.2% 55.1%
NIFTY 100 EQUAL WEIGHT 2% 3.4% 69.3%
NIFTY PHARMA 1.8% 9.6% 49%
NIFTY 100 1.4% 1.3% 58.3%
NIFTY 200 1.4% 1.4% 61.8%
NIFTY 500 1.4% 1.7% 65%
NSE QUALITY 30 1.2% -1% 51%
NIFTY LARGE MIDCAP 250 1.2% 1.7% 72.6%
NIFTY GROWTH SECTOR 15 1.2% 2.1% 56.6%

FAQ [Frequently Asked Questions]


Is AUROPHARMA good for long term investment?

As on 07-May-2021, the Fundamentals of AUROPHARMA are Strong and hence it's good for long term investment! See Financial Performance of AUROBINDO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is AUROPHARMA UnderValued or OverValued?

As on 07-May-2021, AUROPHARMA is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of AUROPHARMA ?

As on 07-May-2021, the Intrinsic Value of AUROPHARMA is Rs. 842.54 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 384.04
Fair Value [Median EV / Sales Model] : Rs. 1,015.93
Fair Value [Median Price / Sales Model] : Rs. 842.54
Median Fair Value of AUROPHARMA : Rs. 842.54

Is AUROPHARMA trading at a Premium or Discount?

As on 07-May-2021, AUROPHARMA is trading at a Premium of 20% based on the Median Intrinsic Value!

Is it right time to buy AUROPHARMA shares?

As on 07-May-2021, AUROPHARMA is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Financial Performance of Industry Peers of AUROPHARMA?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of CIPLA LTD
Financials of BIOCON LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of CADILA HEALTHCARE LTD
Financials of ABBOTT INDIA LTD
Financials of ALKEM LABORATORIES LTD

What are the Frequent Comparisons with AUROPHARMA?

AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs BIOCON LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CADILA HEALTHCARE LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD
AUROBINDO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ALKEM LABORATORIES LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z